Basic Information
| LncRNA/CircRNA Name | MALAT1 |
| Synonyms | NA |
| Region | GRCh38_11:65497688-65506516 |
| Ensemble | ENSG00000251562 |
| Refseq | NR_002819 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | temozolomide | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | glioblastoma |
| ICD-0-3 | NA |
| Methods | qPCR, Luciferase reporter assay, Western blot, RNAi, RNA-seq |
| Sample | GBM tissue, cell lines (U87, A172, U251) |
| Expression Pattern | up-regulated |
| Function Description | we used genome-wide expression analysis in U87 GBM to identify NF-?B-dependent factors altered in response to temozolomide (TMZ) and found the long non-coding RNA (lncRNA) MALAT1 as one of the most significantly upregulated. |
| Pubmed ID | 30940658 |
| Year | 2019 |
| Title | Temozolomide Treatment Induces lncRNA MALAT1 in an NF-?B and p53 Codependent Manner in Glioblastoma. |
External Links
| Links for MALAT1 | GenBank HGNC NONCODE |
| Links for glioblastoma | OMIM COSMIC |